OnKure Therapeutics, Inc.
OKUR•NASDAQ•Healthcare•Biotechnology

About OnKure Therapeutics

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.

Company Information

SectorHealthcare
IndustryBiotechnology
CEONicholas Saccomano
Founded2011
Employees46
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock
Share ClassClass A Shares

Contact Information

Websiteonkuretherapeutics.com
Phone720 307 2892
Address
6707 Winchester Circle, Suite 400 Boulder, Colorado 80301 United States

Corporate Identifiers

CIK0001637715
ISINUS68277Q1058
EIN47-2309515
SIC2834

Leadership Team & Key Executives

Dr. Nicholas A. Saccomano Ph.D.
President, Chief Executive Officer and Director
Jason A. Leverone CPA
Chief Financial Officer
Dr. Samuel Agresta M.D., M.P.H.
Chief Medical Officer
Dr. Dylan Hartley Ph.D.
Chief Scientific Officer
Rogan P. Nunn J.D.
General Counsel and Secretary
Dr. James Blake Ph.D.
Senior Vice President of Computational Drug Discovery
Dr. Kevin S. Litwiler Ph.D.
Senior Vice President of DMPK and Clinical Pharmacology
Dr. Mark L. Boys Ph.D.
Senior Vice President of Discovery Chemistry
Roberta Alton
Senior Vice President of Clinical Operations